Globus Medical

Surgeon familiarity, product breadth and field support keep Globus in musculoskeletal procedure workflows, so procedure demand continues converting into company sales rather than leaking to larger orthopedic competitors. If surgeon preference holds, Globus can keep compounding from a larger base; if it breaks, revenue growth becomes a lagging warning rather than proof of a moat.

The enlarged Globus platform should create operating leverage as overlapping commercial, manufacturing and corporate costs are absorbed over a bigger revenue base, rather than requiring permanently higher spending to defend share. This determines whether growth creates owner earnings or merely buys scale with lower returns.

Globus’s implant-and-instrument model can convert accounting earnings into cash because procedure-critical products, working-capital discipline and collections fund reinvestment without relying heavily on outside capital. Strong cash conversion gives owners more optionality for R&D, surgeon education, tuck-in deals or balance-sheet repair; weak cash conversion would make reported earnings lower quality.

A relatively liquid, equity-heavy balance sheet gives Globus room to fund innovation, surgeon support and integration before financial constraints dictate strategy. Balance-sheet flexibility lets the company play offense in a competitive device market; losing it would raise the cost of growth and reduce per-share upside.